Melanoma study: IBI363
Official title A Study of IBI363 in Subjects with Advanced Solid Malignancies
ClinicalTrials.gov ID: NCT06281678
What this study is testing
What is IBI363?
IBI363 is an investigational medicine being studied as a potential treatment for melanoma.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether IBI363 works and is safe for people with advanced solid cancers.
- Who it's for
- You may be able to join if you have melanoma, non‑small cell lung, colorectal, or renal cell cancer that is advanced and has not responded to other treatments.
- What's involved
- You will receive IBI363 (a study drug) and have regular doctor visits and simple tests to see how you feel.
- Time commitment
- The study lasts several months with visits every few weeks.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- people have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as...
- Male or female people ≥ 18 years old;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- Anticipated life expectancy of ≥ 3 months;
You likely can't join if
- Inadequate bone marrow and organ function;
- Received previous anti-tumor therapy: Any chemotherapy or targeted small molecule therapy (standard or investigational) within 2 weeks or 5 plasma...
- Received live vaccines within 28 days prior to first administration of the study drug or plan on receiving any live vaccine during the study;
- Has adverse reactions resulting from previous antitumor therapies, which have not resolved to Grade 0 or 1 toxicity according to NCI-CTCAE v5.0...
- Undergone major surgery (Craniotomy, thoracotomy or laparotomy, and other surgery according to investigator' discretion, excluding needle biopsy)...
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
- Ocala, Florida, United States
- Plantation, Florida, United States
- Fairway, Kansas, United States
- Dearborn, Michigan, United States
- Troy, Michigan, United States
- Houston, Texas, United States
- Seattle, Washington, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States; Ocala, Florida, United States; Plantation, Florida, United States; Fairway, Kansas, United States; Dearborn, Michigan, United States; Troy, Michigan, United States and 2 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.